{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-084902","form_type":"8-K/A","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.880503+00:00","generated_at":"2026-06-04T03:41:43.185980+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Inhibikase Therapeutics discloses CFO Lees-Rolfe's compensation: $345K salary, 90K option","bullets":["Base salary of $345,000 per annum with discretionary annual target bonus of 30% of base.","Initial stock option for 90,000 shares at $2.16, vesting in three equal annual installments.","Non-CIC termination severance: 9 months base salary plus COBRA reimbursement for 9 months.","CIC termination (within 12 months post-change): 12 months base salary lump sum, full equity vesting, one-time Target Bonus.","Employment Agreement effective April 1, 2024; role as Chief Financial Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-084902","json":"https://secwatch.observer/filing/0001193125-24-084902.json","markdown":"https://secwatch.observer/filing/0001193125-24-084902.md","text":"https://secwatch.observer/filing/0001193125-24-084902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524084902/0001193125-24-084902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524084902/d821381d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:41:43.185980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}